Loxo Oncology Announces Initiation of Phase 1/2 Clinical Trial for Highly Selective, Non-Covalent BTK Inhibitor, LOXO-305
LOXO ONCOLOGY (LOXO)
Last loxo oncology earnings: 11/8 06:45 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.loxooncology.com
Company Research
Source: GlobeNewswire
STAMFORD, Conn., Dec. 21, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company focused on the development and commercialization of highly selective medicines for patients with genomically defined cancers, today announced that it has initiated a Phase 1/2 clinical trial of LOXO-305. LOXO-305 is an investigational, highly selective, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor specifically designed to address acquired resistance and intolerance in patients previously treated with FDA-approved BTK inhibitors. "We are pleased to initiate the clinical trial for our fourth novel drug candidate,” said Josh Bilenker, M.D., chief executive officer of Loxo Oncology. “FDA-approved BTK inhibitors, which all covalently (irreversibly) bind to their targets, have meaningfully improved the lives of patients with certain B-cell leukemias and lymphomas. However, we are now learning that many patients are discontinuing these therapies due to disease progr
Show less
Read more
Impact Snapshot
Event Time:
LOXO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LOXO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LOXO alerts
High impacting LOXO ONCOLOGY news events
Weekly update
A roundup of the hottest topics